Han Soo Yoo1, Seok Jong Chung1, Su Jin Chung1, Hyojeong Moon2, Jung Su Oh2, Jae Seung Kim2, Jin Yong Hong3, Byoung Seok Ye1, Young Ho Sohn1, Phil Hyu Lee4. 1. Department of Neurology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. 2. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. Yonsei University Wonju College of Medicine, Wonju, South Korea. 4. Department of Neurology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. phlee@yuhs.ac.
Abstract
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset. METHODS: From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years. Based on the time from PD onset, LID was classified as early, intermediate or late onset. We then compared DAT availability in the striatal subregions of the patients in the three groups. RESULTS: The demographic characteristics did not differ among the three patient groups except for earlier intervention of levodopa therapy in the early LID onset group (p = 0.001). After adjusting for age at PD onset, gender, timing of levodopa therapy from PD onset, and the severity of PD motor symptoms, DAT activity in the posterior putamen was found to be significantly lower in the early LID onset group than in the late LID onset group (p = 0.017). Multivariate linear regression analysis showed that low DAT activity in the posterior putamen was significantly associated with the early appearance of LID in the early LID onset group (β = 16.039, p = 0.033). CONCLUSION: This study demonstrated that low DAT activity in the posterior putamen at baseline is a major risk factor for the early onset of LID in patients with PD, suggesting that the degree of presynaptic dopaminergic denervation plays an important role in determining the timing of LID onset.
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset. METHODS: From among 412 drug-naive PDpatients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years. Based on the time from PD onset, LID was classified as early, intermediate or late onset. We then compared DAT availability in the striatal subregions of the patients in the three groups. RESULTS: The demographic characteristics did not differ among the three patient groups except for earlier intervention of levodopa therapy in the early LID onset group (p = 0.001). After adjusting for age at PD onset, gender, timing of levodopa therapy from PD onset, and the severity of PD motor symptoms, DAT activity in the posterior putamen was found to be significantly lower in the early LID onset group than in the late LID onset group (p = 0.017). Multivariate linear regression analysis showed that low DAT activity in the posterior putamen was significantly associated with the early appearance of LID in the early LID onset group (β = 16.039, p = 0.033). CONCLUSION: This study demonstrated that low DAT activity in the posterior putamen at baseline is a major risk factor for the early onset of LID in patients with PD, suggesting that the degree of presynaptic dopaminergic denervation plays an important role in determining the timing of LID onset.
Authors: N D Volkow; Y S Ding; J S Fowler; G J Wang; J Logan; S J Gatley; R Hitzemann; G Smith; S D Fields; R Gur Journal: J Nucl Med Date: 1996-04 Impact factor: 10.057
Authors: M Péchevis; C E Clarke; P Vieregge; B Khoshnood; C Deschaseaux-Voinet; G Berdeaux; M Ziegler Journal: Eur J Neurol Date: 2005-12 Impact factor: 6.089
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2001-09 Impact factor: 6.200
Authors: U Scheffel; J R Lever; P Abraham; K R Parham; W B Mathews; T Kopajtic; F I Carroll; M J Kuhar Journal: Synapse Date: 1997-04 Impact factor: 2.562
Authors: Giovanni Fabbrini; Jonathan M Brotchie; Francisco Grandas; Masahiro Nomoto; Christopher G Goetz Journal: Mov Disord Date: 2007-07-30 Impact factor: 10.338
Authors: Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop Journal: Exp Neurol Date: 2020-05-05 Impact factor: 5.330
Authors: Yang Hyun Lee; Jungho Cha; Seok Jong Chung; Han Soo Yoo; Young H Sohn; Byoung Seok Ye; Phil Hyu Lee Journal: Sci Rep Date: 2019-07-19 Impact factor: 4.379
Authors: Han Soo Yoo; Yong Ho Choi; Seok Jong Chung; Yang Hyun Lee; Byoung Seok Ye; Young H Sohn; Jong-Min Lee; Phil Hyu Lee Journal: Ann Clin Transl Neurol Date: 2019-10-23 Impact factor: 4.511
Authors: Han Soo Yoo; Eun-Chong Lee; Seok Jong Chung; Byoung Seok Ye; Young H Sohn; Joon-Kyung Seong; Phil Hyu Lee Journal: Sci Rep Date: 2022-07-25 Impact factor: 4.996